Lyell Immunopharma co-led a series A round for the gene therapy developer, which partially exploits UW research.
Outpace Bio, a US-based smart cell therapy developer partially based on research at University of Washington, completed a $30m series A round yesterday backed by WRF Capital, the early-stage investment unit of commercialisation firm Washington Research Foundation.
Cellular therapy developer Lyell Immunopharma and venture capital firm Artis Ventures co-led the round, which also attracted Abstract Ventures, Civilization Ventures, Mubadala Capital, Playground Global and Sahsen Ventures.
Outpace is working on synthetic proteins using its own biological software and hardware,…
